__timestamp | Geron Corporation | Opthea Limited |
---|---|---|
Wednesday, January 1, 2014 | 16758000 | 2652041 |
Thursday, January 1, 2015 | 17793000 | 2361587 |
Friday, January 1, 2016 | 18761000 | 4472869 |
Sunday, January 1, 2017 | 19287000 | 5030957 |
Monday, January 1, 2018 | 18707000 | 4988941 |
Tuesday, January 1, 2019 | 20893000 | 5196412 |
Wednesday, January 1, 2020 | 25678000 | 6652774 |
Friday, January 1, 2021 | 29665000 | 18418247 |
Saturday, January 1, 2022 | 43628000 | 24827066 |
Sunday, January 1, 2023 | 69135000 | 41896408 |
Monday, January 1, 2024 | 15488619 |
Unlocking the unknown
In the ever-evolving landscape of corporate finance, Selling, General, and Administrative (SG&A) expenses serve as a critical indicator of a company's operational efficiency. This analysis juxtaposes the SG&A expenses of Opthea Limited and Geron Corporation from 2014 to 2023, offering a fascinating glimpse into their financial strategies.
Opthea Limited has shown a consistent increase in SG&A expenses, rising from approximately $2.4 million in 2015 to a peak of $41.9 million in 2023. This represents a staggering 1,670% increase over the period, reflecting the company's aggressive expansion and investment in administrative capabilities.
Geron Corporation, on the other hand, experienced a more volatile trajectory. Starting at $16.8 million in 2014, their SG&A expenses surged to $69.1 million by 2023, marking a 311% increase. This sharp rise, particularly noticeable from 2021 onwards, suggests a strategic pivot towards scaling operations.
Both companies exhibit unique financial narratives, with Opthea's steady growth contrasting Geron's more dramatic shifts. These trends underscore the diverse strategies companies employ to navigate the competitive corporate landscape.
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Opthea Limited
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Ionis Pharmaceuticals, Inc. vs Opthea Limited: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Opthea Limited and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Opthea Limited or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Cost Management Insights: SG&A Expenses for ACADIA Pharmaceuticals Inc. and Geron Corporation
Who Optimizes SG&A Costs Better? Geron Corporation or Wave Life Sciences Ltd.